How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,310 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea

duration maximal 5 days [ Time Frame: 5 days ] Duration of diarrhea is defined by date and time of the evacuation of the final diarrheal stool derived from the daily diary Secondary Outcome Measures : Number of recovered subjects [ Time Frame: 5 days ] Number of recovered subjects Global Physician Assessment at the end of treatment [ Time Frame: 5 days ] scores 1-6 Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal (...) Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2018 Clinical Trials

22. Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes. Other Name: Pepto Bismol Placebo Comparator: Placebo Placebo oral tablet 4 bid Drug: Placebo Oral Tablet Placebo manufactured to mimic pepto bismol Outcome Measures Go to Primary Outcome Measures : Traveler's diarrhea [ Time Frame: Change from baseline through 10 days post-travel ] Self-reported TD Secondary Outcome Measures : Gut AMR genes [ Time Frame: Once within 7 days (before travel); once (...) Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bismuth

2018 Clinical Trials

23. Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

24. Transcutaneous electric nerve stimulation over acupoints for patients with diarrhea-predominant irritable bowel syndrome: Protocol for systematic review and meta-analysis. (PubMed)

Transcutaneous electric nerve stimulation over acupoints for patients with diarrhea-predominant irritable bowel syndrome: Protocol for systematic review and meta-analysis. At present, drug therapy for diarrhea-predominant irritable bowel syndrome (IBS-D) has made great progress; however, it does not often produce a satisfying curative effect. Transcutaneous electric nerve stimulation over acupoints (Acu-TENS) might be more effective in improving patient's symptoms and producing fewer side (...) electronic databases (Biomedical Literature Database, CNKI, VIP, Wanfang Database) will be searched from their inception to November 26, 2018. Randomized controlled trials that evaluated the effect of Acu-TENS on patients with IBS-D will be included. The primary outcome measures will include average weekly stool frequency, visual analog scale (VAS), and the Bristol scale. The secondary outcome measures will include the MOS 36-item short-form health survey (SF-36), IBS Quality of Life Questionnaire (IBS

2018 Medicine

25. A Study of Colesevelam for Lenalidomide-Associated Diarrhea

lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease (...) . The primary end-point is improvement of diarrhea to grade 1 or better according to the CTCAE 5.0 scale by 4 weeks of treatment with colesevelam. Secondary Outcome Measures : GI symptom assessment [ Time Frame: 4 weeks ] To assess GI symptoms using Patient Reported Outcomes within the Common Terminology Criteria for Adverse Events Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor

2018 Clinical Trials

26. Green Banana (GB) Mixed Diet in the Management of Persistent Diarrhea (PD)

the child will be declared as treatment failure. Outcome Measures Go to Primary Outcome Measures : By day 5, percentage of children recovered from diarrhea by the study diets [ Time Frame: 5 days ] Recovery from diarrhea is desired in PD.so, study outcome will be measured by calculating the percentage of children recovered from diarrhea by the study diets by day 5. Secondary Outcome Measures : By day 7, percentage of children recovered from diarrhea by the study diets [ Time Frame: 7 days ] Recovery (...) from diarrhea is desired in PD. So, one of the secondary outcome is to find the percentage of children recovered from diarrhea by the study diets by day 7. Frequency of stool in different days in different study diet groups [ Time Frame: 7 days ] One of the study outcome is to record frequency of bowel movement whether reduced or increased. Consistency of stool in different days in different study diet groups [ Time Frame: 7 days ] One of the study outcome is to record stool consistency whether

2017 Clinical Trials

27. Oral Administration of Tannins and Flavonoids in Children With Acute Diarrhea

number and consistency of stools (compared with the period before the onset of diarrhea). Secondary outcomes were the evaluation of vomiting, body weight, possible need of hospitalization, compliance to therapy. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 60 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Oral Administration (...) complex of Tannins and Flavonoids used for acute diarrhea in children Drug: Standard Oral Rehydration Standard oral rehydration as suggested by ESPGHAN guidelines Active Comparator: Group 2 Group 2 consisting of 30 children who received only SOR. Drug: Standard Oral Rehydration Standard oral rehydration as suggested by ESPGHAN guidelines Outcome Measures Go to Primary Outcome Measures : effectiveness of a medical device made of Actitan-F in the treatment of acute diarrhea, valuated on the basis

2017 Clinical Trials

28. Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children.

). Patient has celiac disease, or a positive serological test for celiac disease and the condition has not been ruled out by endoscopic biopsy. Patient has any congenital and/or acquired malabsorption syndrome (eg, Shwachman-Diamond syndrome). Patient has a history of a microbiologically documented (ie, stool culture or medical history) GI infection within 3 months prior to Screening. Patient has a known lactose or fructose intolerance that is associated with diarrhea, abdominal pain or discomfort (...) Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children. Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

29. Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

: Day 10 (End of Treatment) ] Mean fecal concentrations of cadazolid obtained after 10 days of treatment will be reported Secondary Outcome Measures : Clinical cure rate during Part A [ Time Frame: Day 10 (End of Treatment) + 2 days ] Percentage of subjects reported as with a clinical cure. Clinical Cure is defined as: • <3 unformed bowel movement (UBM) per day (or no water diarrhea if subjects < 2 years of age), for at least 2 consecutive days between first dose of study treatment up to end (...) Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD) Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2017 Clinical Trials

30. Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer (PubMed)

TJ-14 (7.5 g/day) and minocycline (100 mg/day) were administered simultaneously from the start of afatinib administration. The primary end point was the incidence of ≥ grade 3 (G3) diarrhea (increase of ≥7 stools/day over baseline) during the first 4 weeks of treatment. The secondary end points were the incidence of ≥ G3 oral mucositis (severe pain interfering with oral intake) and $ G3 skin toxicity (severe or medically significant but not immediately life-threatening).A total of 29 patients (...) Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer Diarrhea and oral mucositis induced by afatinib can cause devastating quality of life issues for patients undergoing afatinib treatment. Several studies have shown that hangeshashin-to (TJ-14) might be useful for chemotherapy-induced diarrhea and oral mucositis. In this study, we investigated the prophylactic effects of TJ-14

Full Text available with Trip Pro

2017 OncoTargets and therapy

31. Chronic Diarrhea in Dogs – Retrospective Study in 136 Cases (PubMed)

Chronic Diarrhea in Dogs – Retrospective Study in 136 Cases Chronic diarrhea (CD) is common in dogs, and information on frequency and distribution of primary and secondary causes is lacking.To evaluate underlying causes and predictors of outcome in dogs with CD.One hundred and thirty-six client-owned dogs with CD (≥3 weeks duration).Retrospective review of medical records (Small Animal Clinic, Freie Universität Berlin, Germany, 09/2009-07/2011). Quantification of final diagnoses (...) %), and in one dog each mechanical disease or systemic vasculitis. Secondary causes were diagnosed in 10% of dogs: exocrine pancreatic (6%), endocrine (2%), and in one dog each hepatic, renal, and cardiac disease. In total, 87% of dogs had clinical remission, whereas 13% died or did not respond to treatment: Lack of recovery was frequently recorded for dogs with primary inflammatory (idiopathic) or neoplastic disease and was significantly associated with increased disease severity scores (P = .005), anemia

Full Text available with Trip Pro

2017 Journal of Veterinary Internal Medicine

32. Evaluation of Gelatin Tannate Against Symptoms of Acute Diarrhea in Pediatric Patients (PubMed)

patients with acute diarrhea. MATERIAL AND METHODS This was a randomized, controlled, double-blind, parallel-group, single-center study comparing gelatin tannate plus ORS (103 patients) with ORS plus placebo (100 patients) in children aged 3 months to 12 years with infectious or noninfectious acute diarrhea. Details about stool consistency and total time to resolution of diarrhea comprised the primary study endpoints. Secondary study endpoints included symptoms of diarrhea at 12, 24, 36, 48, and 72 (...) Evaluation of Gelatin Tannate Against Symptoms of Acute Diarrhea in Pediatric Patients BACKGROUND Acute diarrhea is the second most common cause of morbidity and mortality worldwide, especially in children aged ≤3 years. Some drugs (e.g., the mucoprotector gelatin tannate) plus a reduced osmolality oral rehydration solution (ORS) may effectively reduce symptom duration and severity. The current trial was therefore designed to assess the efficacy and safety of gelatin tannate in pediatric

Full Text available with Trip Pro

2017 Medical science monitor : international medical journal of experimental and clinical research Controlled trial quality: predicted high

33. A Double Blind, Randomized, Placebo-Controlled Trial of Lactobacillus acidophilus for the Treatment of Acute Watery Diarrhea in Vietnamese Children. (PubMed)

. Children meeting the inclusion criteria (acute watery diarrhea) were randomized to receive either 2 daily oral doses of 2 × 10 CFUs of a local probiotic containing Lactobacillus acidophilus or placebo for 5 days as an adjunct to standard of care. The primary end point was time from the first dose of study medication to the start of the first 24-hour period without diarrhea. Secondary outcomes included the total duration of diarrhea and hospitalization, daily stool frequency, treatment failure, daily (...) fecal concentrations of rotavirus and norovirus, and Lactobacillus colonization.One hundred and fifty children were randomized into each study group. The median time from the first dose of study medication to the start of the first 24-hour diarrhea-free period was 43 hours (interquartile range, 15-66 hours) in the placebo group and 35 hours (interquartile range, 20-68 hours) in the probiotic group (acceleration factor 1.09 [95% confidence interval, 0.78-1.51]; P = 0.62). There was also no evidence

2017 Pediatric Infectious Dsease Journal Controlled trial quality: predicted high

34. Risk-factors Associated with Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review. (PubMed)

Risk-factors Associated with Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review. Very early onset inflammatory bowel disease (VEO-IBD) represents a diagnostic and treatment challenge. Here we present a case of VEO-IBD secondary to a mutation in BIRC4 gene, which encodes X-linked inhibitor of apoptosis protein (XIAP), in a 17 month-old male with severe failure to thrive, intractable diarrhea and hepatosplenomegaly. Endoscopy and histology identified only (...) patients with VEO-IBD secondary to XIAP deficiency develop symptoms that are refractory to medical and surgical management, while initial reports suggest that allogeneic hematopoietic stem cell transplantation (HSCT), with reduced intensity conditioning, can successfully induce long lasting remission and may even be curative. We propose that in patients with XIAP deficiency a constellation of symptoms including colitis at an early age, severe failure to thrive and splenomegaly/hepatosplenomegaly can

2019 Journal of Pediatric Gastroenterology and Nutrition

35. Risk-factors Associated With Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review. (PubMed)

Risk-factors Associated With Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review. Very early onset inflammatory bowel disease (VEO-IBD) represents a diagnostic and treatment challenge. Here we present a case of VEO-IBD secondary to a mutation in BIRC4 gene, which encodes X-linked inhibitor of apoptosis protein (XIAP), in a 17-month-old boy with severe failure to thrive, intractable diarrhea, and hepatosplenomegaly. Endoscopy and histology identified only (...) with VEO-IBD secondary to XIAP deficiency develop symptoms that are refractory to medical and surgical management, while initial reports suggest that allogeneic hematopoietic stem cell transplantation (HSCT), with reduced intensity conditioning, can successfully induce long-lasting remission and may even be curative. We propose that in patients with XIAP deficiency a constellation of symptoms including colitis at an early age, severe failure to thrive, and splenomegaly/hepatosplenomegaly can identify

2019 Journal of Pediatric Gastroenterology and Nutrition

36. Acute Diarrhea in Adults and Children: A Global Perspective

Linking the main symptoms to the causes of acute diarrhea— enterohemorrhagic E. coli (EHEC) 7 Table 4 Clinical features of infection with selected diarrheal pathogens 8 Table 5 Medical assessment in diarrhea 8 Table 6 Assessment of dehydration using the “Dhaka method” 9 Table 7 Patient history details and causes of acute diarrhea 10 Table 8 Incubation period and likely causes of diarrhea 10 Table 9 Patient details and bacterial testing to consider 10 Table 10 Prognostic factors in children 11 Table 11 (...) /often not present. Clinical evaluation The initial clinical evaluation of the patient (Table 5) should focus on: • Assessing the severity of the illness and the magnitude (degree) of dehydration (Table 6) • Determining likely causes on the basis of the history and clinical findings, including stool characteristics Table 5 Medical assessment in diarrhea Patient history Physical examination Onset, stool frequency, type and volume Presence of blood Vomiting Medicines received Past medical history

2012 World Gastroenterology Organisation

37. Probiotics for the Prevention of Antibiotic-Associated Diarrhea

will power the trial based GRSd, a more conservative AAD incidence (23%). The investigators will also power the trial for a smaller treatment effect (39% relative risk reduction). Secondary Outcome Measures : Severity of AAD [ Time Frame: 2 weeks after antibiotic completion ] The investigators will assess severity using the qPAD and the investigators will employ definitions for diarrhea from the Canadian Nosocomial Infection Surveillance Program, modified for use in children, defined as: severe: ≥6 loose (...) Probiotics for the Prevention of Antibiotic-Associated Diarrhea Probiotics for the Prevention of Antibiotic-Associated Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Probiotics for the Prevention

2016 Clinical Trials

38. Prevention of Irinotecan Induced Diarrhea by Probiotics

of grade 3/4 diarrhea) of probiotic formula PROBIO-FIX INUM® given orally to patients with colorectal cancer starting new line of irinotecan based chemotherapy. Response will be defined as prevention of grade 3/4 diarrhea according to definition of NCI CTC version 4.0 Secondary Outcome Measures : Progression-free survival [ Time Frame: 1 year ] Progression-free survival period will be evaluated according to standard protocol. Prevention of any grade of diarrhea [ Time Frame: 6 weeks ] To determine (...) Prevention of Irinotecan Induced Diarrhea by Probiotics Prevention of Irinotecan Induced Diarrhea by Probiotics - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Prevention of Irinotecan Induced Diarrhea

2016 Clinical Trials

39. Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial

Identifier: NCT02871908 Recruitment Status : Completed First Posted : August 18, 2016 Last Update Posted : March 20, 2018 Sponsor: Medical University of Warsaw Information provided by (Responsible Party): Hanna Szajewska, Medical University of Warsaw Study Details Study Description Go to Brief Summary: The aim of this study is to assess the effect of Lactobacillus reuteri DSM 17938 administration for the prevention of diarrhea and AAD in children. Condition or disease Intervention/treatment Phase (...) for a minimum of 24 hours during antibiotic treatment. AAD will be diagnosed in cases of diarrhea, defined clinically as above, caused by C. difficile or for otherwise unexplained diarrhea (i.e., negative laboratory stool tests for infectious agents). In all cases, loose or watery stools will correspond to scores of 5 to 7 on the BSF scale or A-consistency on the AISS. Secondary Outcome Measures : infectious diarrhea [ Time Frame: during antibiotic treatment, an average of 10 days and 7 days of follow up

2016 Clinical Trials

40. An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

hours ] Improvement in management of persistent grade 2 diarrhea as measured by proportion of responders to less than or equal to grade 1 [ Time Frame: Up to 78 hours ] Secondary Outcome Measures : Number of days to improvement to less than grade 1 diarrhea [ Time Frame: Randomization up to 12 weeks ] Quality of life as measured by European Quality of Life-5 Dimensions Questionnaire (EQ-5D) [ Time Frame: Up to 12 weeks ] Number of hospitalizations [ Time Frame: Up to 12 weeks ] Duration (...) An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>